GLPG vs. NAMS, SNDX, AGIO, EWTX, GPCR, AMRX, EVO, CPRX, HRMY, and AMPH
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Agios Pharmaceuticals (AGIO), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), Amneal Pharmaceuticals (AMRX), Evotec (EVO), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
NewAmsterdam Pharma has a net margin of 0.00% compared to Galapagos' net margin of -26.25%. NewAmsterdam Pharma's return on equity of 0.00% beat Galapagos' return on equity.
Galapagos received 454 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Galapagos has higher revenue and earnings than NewAmsterdam Pharma.
Galapagos presently has a consensus price target of $34.50, suggesting a potential upside of 16.44%. NewAmsterdam Pharma has a consensus price target of $33.25, suggesting a potential upside of 65.51%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Galapagos.
In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Galapagos. MarketBeat recorded 7 mentions for NewAmsterdam Pharma and 5 mentions for Galapagos. NewAmsterdam Pharma's average media sentiment score of 0.39 beat Galapagos' score of 0.21 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.
Galapagos has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
32.5% of Galapagos shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
NewAmsterdam Pharma beats Galapagos on 12 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
